59 results
8-K
EX-99.1
HEPA
Hepion Pharmaceuticals Inc
7 Dec 23
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
8:41am
taking in account current market environment
Cash runway extended into Q2 2025
EDISON, N.J., December 7, 2023 - Hepion Pharmaceuticals, Inc … on maximizing stockholder value within the current financial environment and NASH drug development landscape. Currently 131 patients are being treated in our
8-K
EX-10.1
HEPA
Hepion Pharmaceuticals Inc
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws … (collectively, “Hazardous Materials”) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage
424B5
1aeay1
2 Oct 23
Prospectus supplement for primary offering
4:52pm
8-K
EX-1.1
e9o76
21 Jul 23
Entry into a Material Definitive Agreement
4:41pm
424B5
88e89ua 7hn1j
21 Jul 23
Prospectus supplement for primary offering
4:39pm
8-K
EX-10.1
v4cbjemp9wl466eh
8 Nov 22
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
8:41pm
8-K
EX-99
guajd re1rv
21 Dec 21
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer
8:25am
8-K
EX-99.1
ooh31pncxb4tsd3j93of
17 Feb 21
Hepion Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
8:06am